See beyond appearances
1 in 3 cancers is a skin cancer
Skin cancer is the most commonly occurring cancer in humans, with an incidence that has steadily increased worldwide. The prognosis of advanced melanoma is poor, and carcinomas are associated with high morbidity.
60% biopsies result in benign diagnoses
Although dermoscopy is a useful tool for clinical examination, the sensitivity of dermoscopic monitoring is limited by melanomas that may arise in normal skin or in clinically benign nevi that were not initially photographed (link).
20% skin cancers missed at early stage
Dermoscopy improves the diagnostic accuracy for melanoma but only for experienced examiners. Dermoscopy by untrained or less experienced examiners is no better than clinical inspection without dermoscopy (link).
Discover deepLive™
DAMAE Medical develops deepLive™ medical device, the new best-in-class imaging system pairing penetration and cellular resolution in 3D. deepLive™ is adapted to the imaging of multiple skin conditions, promoting efficient, reassuring and non-invasive patient management.
Based on LC-OCT™ innovative technology
deepLive™ integrates LC-OCT (Line-field Confocal Optical Coherence Tomography) technology which provides a unique 3D imaging modality, allowing the user to switch from a histology-like vertical mode to a confocal-like horizontal mode,
and to record a 3D stack of tissue volumes in situ.
Navigations in LC-OCT™ 3D stacks
LC-OCT™ imaging of the back of a hand
.png)
LC-OCT™ imaging of a fingerprint
User Testimonial
Prof. Mariano Suppa from the Dermatology Department of the Erasme Hospital, ULB Brussels, shares his experience with deepLive™.
LIST OF PUBLICATIONS
Access to the library on Zotero.org
Quantitative skin analyses
adapted to your studies
-
Skin Surface 3D segmentation
-
Dermo-Epidermal Junction 3D segmentation
-
Keratinocytes distribution
-
Keratinocytes density with depth
-
Collagen fibers segmentation
Our company
2014
> Company established by Anaïs BARUT (CEO), David SIRET (CTO), Arnaud DUBOIS (CSO) who filed the patent protecting LC-OCT's technology
> Proof of concept of LC-OCT vertical imaging
2015
> First LC-OCT images performed on fresh biopsies of suspected skin cancer
> Validation of the potential of LC-OCT vertical imaging for the 2 main types of skin cancer: carcinoma and melanoma
2016
> First clinical demonstrator installed at the Saint-Etienne University Hospital
> Winner of the Digital Innovation Competition organized by Bpifrance
> Signature of the exclusive license agreement for LC-OCT technology
2017
> Closing of a €2 million investment round with Kurma Partners, Idinvest Partners, News Invest, Paris-Saclay Seed Fund co-managed by Partech Ventures, and private investors
> Obtaining ISO 13485 certificate
> First proof of concept of LC-OCT 3D
2018
> Winner of the World Competition of Innovation organized by Bpifrance
> Miniaturized LC-OCT 2D in a handheld probe
> Obtaining CE-marking LC-OCT 2D
> Installation of LC-OCT 2D devices in hospitals
> First scientific publication: A. Dubois and al., “LC-OCT for high-resolution noninvasive imaging of skin tumors”, JBO 23, 106007
2019
> Miniaturized LC-OCT 3D in a handheld probe > Obtaining CE-marking LC-OCT 3D
> Manufacturing of 10 LC-OCT 3D devices
> Launch of clinical validation of LC-OCT 3D
2020
> Integration of the live dermoscopic camera inside the handheld probe
> Obtaining the CE mark for deepLive™
> First descriptive clinical publications
> Commercial launch of deepLive™ in Europe
2021
> 30 centers installed in 9 countries in Europe, Japan and the United States
> Publication of the 50th scientific paper on LC-OCT and its applications
> Implementation of a scalable production strategy with industrial partners
Prof. Arnaud Duboispresents LC-OCT technology
3 key numbers in the development of DAMAE Medical
Contact us
DAMAE Medical
14 rue Sthrau
75013 Paris
France
If you are looking for a position or an internship, send your CV on this page:
www.damae-medical.nous-recrutons.fr
We will get back to you as soon as possible!